These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17653499)

  • 1. Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects.
    Frolich L
    J Nutr Health Aging; 2007; 11(4):357-8. PubMed ID: 17653499
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
    Wong VS
    Neurology; 2007 Aug; 69(8):809; author reply 809-10. PubMed ID: 17709718
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuropsychiatric outcome for clinical trials.
    Robert P; Verhey FR; Aalten P; Cortes F; Byrne EJ
    J Nutr Health Aging; 2007; 11(4):345-7. PubMed ID: 17653496
    [No Abstract]   [Full Text] [Related]  

  • 5. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological treatment in severe dementia].
    Jouanny P; Belliard S; Bentué-Ferrer D; Michel O; Allain H
    Psychol Neuropsychiatr Vieil; 2005 Mar; 3 Suppl 1():S51-5. PubMed ID: 15899605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Ferris SH; Lucca U; Mohs R; Dubois B; Wesnes K; Erzigkeit H; Geldmacher D; Bodick N
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():34-8. PubMed ID: 9305514
    [No Abstract]   [Full Text] [Related]  

  • 9. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.
    Rockwood K; Black S; Bedard MA; Tran T; Lussier I;
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia.
    Warner J; Butler R
    Clin Evid; 2002 Jun; (7):846-66. PubMed ID: 12230710
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 13. [Challenging pharmacotherapy in dementia].
    Ihl R
    MMW Fortschr Med; 2009 Mar; 151(13):46-8. PubMed ID: 19504818
    [No Abstract]   [Full Text] [Related]  

  • 14. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Gauthier S; Bodick N; Erzigkeit E; Feldman H; Geldmacher DS; Huff J; Mohs R; Orgogozo JM; Rogers S
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():6-7. PubMed ID: 9305507
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-Alzheimer drugs: ethical aspects of research and practice].
    Berghmans RL
    Tijdschr Gerontol Geriatr; 2000 Jun; 31(3):100-6. PubMed ID: 10900662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relief for caregivers. Anti-dementia drug saves costs].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697297
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease.
    Bhattacharya S; Vogel A; Hansen ML; Waldorff FB; Waldemar G
    Dement Geriatr Cogn Disord; 2010; 30(4):327-33. PubMed ID: 20924186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Reisberg B; Schneider L; Doody R; Anand R; Feldman H; Haraguchi H; Kumar R; Lucca U; Mangone CA; Mohr E; Morris JC; Rogers S; Sawada T
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():8-18. PubMed ID: 9305508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tense prescriptions? Alzheimer medications and the anthropology of uncertainty.
    Leibing A
    Transcult Psychiatry; 2009 Mar; 46(1):180-206. PubMed ID: 19293285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia.
    Warner J; Butler R; Jackson E
    Clin Evid; 2002 Dec; (8):927-50. PubMed ID: 12603921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.